PL3233192T3 - Kompozycje i sposoby ukierunkowanego dostarczania cytokin - Google Patents
Kompozycje i sposoby ukierunkowanego dostarczania cytokinInfo
- Publication number
- PL3233192T3 PL3233192T3 PL15870897T PL15870897T PL3233192T3 PL 3233192 T3 PL3233192 T3 PL 3233192T3 PL 15870897 T PL15870897 T PL 15870897T PL 15870897 T PL15870897 T PL 15870897T PL 3233192 T3 PL3233192 T3 PL 3233192T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- methods
- cytokine delivery
- targeted cytokine
- targeted
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462091898P | 2014-12-15 | 2014-12-15 | |
| US201562243829P | 2015-10-20 | 2015-10-20 | |
| PCT/US2015/065872 WO2016100375A2 (en) | 2014-12-15 | 2015-12-15 | Compositions and methods for targeted cytokine delivery |
| EP15870897.4A EP3233192B1 (en) | 2014-12-15 | 2015-12-15 | Compositions and methods for targeted cytokine delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3233192T3 true PL3233192T3 (pl) | 2021-11-02 |
Family
ID=56127836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15870897T PL3233192T3 (pl) | 2014-12-15 | 2015-12-15 | Kompozycje i sposoby ukierunkowanego dostarczania cytokin |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10793613B2 (pl) |
| EP (3) | EP3875152B1 (pl) |
| DK (1) | DK3233192T3 (pl) |
| ES (1) | ES2881374T3 (pl) |
| HR (1) | HRP20211113T1 (pl) |
| HU (1) | HUE055460T2 (pl) |
| PL (1) | PL3233192T3 (pl) |
| PT (1) | PT3233192T (pl) |
| WO (1) | WO2016100375A2 (pl) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3875152B1 (en) | 2014-12-15 | 2024-04-10 | Washington University | Compositions and methods for targeted cytokine delivery |
| CA3011374A1 (en) * | 2016-02-05 | 2017-08-10 | Washington University | Compositions and methods for targeted cytokine delivery |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| DK3661954T3 (da) | 2017-08-03 | 2022-04-19 | Amgen Inc | Interleukin-21-muteiner og fremgangsmåder til behandling |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| JP2021516045A (ja) | 2018-02-28 | 2021-07-01 | ファイザー・インク | Ｉｌ−１５バリアントおよびその使用 |
| AU2020226493B2 (en) * | 2019-02-18 | 2025-10-23 | Recourse Biologics, Inc. | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class l-like protein (OMCP) and tumor-specific binding partner |
| EP3969119A1 (en) | 2019-05-17 | 2022-03-23 | Xencor, Inc. | Il-7-fc-fusi0n proteins |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| AR121891A1 (es) * | 2020-04-22 | 2022-07-20 | Merck Sharp & Dohme | CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO |
| WO2022009123A1 (en) * | 2020-07-09 | 2022-01-13 | Eutilex Co., Ltd. | Il-2 variants |
| EP4232071A4 (en) | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| AU2022275666A1 (en) | 2021-05-19 | 2023-12-07 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| WO2025174838A1 (en) * | 2024-02-15 | 2025-08-21 | The Johns Hopkins University | Compositions of an artificial lymph node matrix and methods of preparing the same |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4529561A (en) | 1978-03-24 | 1985-07-16 | The Regents Of The University Of California | Method for producing liposomes in selected size range |
| US4241046A (en) | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4925661A (en) | 1984-04-19 | 1990-05-15 | Leaf Huang | Target-specific cytotoxic liposomes |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US4755388A (en) | 1984-11-09 | 1988-07-05 | The Regents Of The University Of California | Liposome-encapsulated 5-fluoropyrimidines and methods for their use |
| DE3542773A1 (de) | 1985-12-04 | 1987-06-11 | Roehm Pharma Gmbh | Hautwirksame pharmaka mit liposomen als wirkstofftraeger |
| US4828837A (en) | 1987-03-30 | 1989-05-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition, its production and application |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5043164A (en) | 1989-01-17 | 1991-08-27 | The University Of Tennessee Research Corporation | Blood-stable, cholesterol-free liposomes |
| US5064655A (en) | 1989-02-24 | 1991-11-12 | Liposome Technology, Inc. | Liposome gel composition and method |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US6303573B1 (en) | 1999-06-07 | 2001-10-16 | The Burnham Institute | Heart homing peptides and methods of using same |
| GB9916703D0 (en) | 1999-07-16 | 1999-09-15 | Alcami Antonio | Viral protein binding compositions and methods |
| WO2001021204A1 (en) | 1999-09-20 | 2001-03-29 | The John P. Robarts Research Institute | Therapeutic uses of m3 polypeptide |
| US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
| US20060183161A1 (en) | 2000-07-17 | 2006-08-17 | Martin Nicklin | IL-ILI gene and polypeptide products |
| US7371371B2 (en) * | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| PT1454138E (pt) | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| AU2006301163B2 (en) | 2005-10-14 | 2012-02-23 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| KR101615935B1 (ko) | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| US9273136B2 (en) | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
| WO2010091637A1 (en) | 2009-02-10 | 2010-08-19 | Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
| HUE029139T2 (hu) | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EP2723380B1 (en) * | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| CN104470535A (zh) | 2012-03-29 | 2015-03-25 | 阿尔托生物科学有限公司 | 用于治疗肿瘤的方法 |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| JP6666240B2 (ja) | 2013-04-12 | 2020-03-13 | フランチェスカ， サベリオ ラ | 移植のための臓器の改良 |
| WO2014201308A1 (en) | 2013-06-12 | 2014-12-18 | Washington University | Endothelial-targeted adenoviral vectors, methods and uses therefor |
| AU2014413902A1 (en) | 2014-12-08 | 2017-06-15 | The University Of Queensland | Methods and compositions for treating or preventing flavivirus infections |
| EP3875152B1 (en) | 2014-12-15 | 2024-04-10 | Washington University | Compositions and methods for targeted cytokine delivery |
| CA3011374A1 (en) | 2016-02-05 | 2017-08-10 | Washington University | Compositions and methods for targeted cytokine delivery |
| KR102687530B1 (ko) * | 2016-05-04 | 2024-07-25 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| US11351227B2 (en) | 2017-04-27 | 2022-06-07 | Washington University | Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof |
-
2015
- 2015-12-15 EP EP21155548.7A patent/EP3875152B1/en active Active
- 2015-12-15 EP EP24167783.0A patent/EP4382535A3/en active Pending
- 2015-12-15 HU HUE15870897A patent/HUE055460T2/hu unknown
- 2015-12-15 PL PL15870897T patent/PL3233192T3/pl unknown
- 2015-12-15 HR HRP20211113TT patent/HRP20211113T1/hr unknown
- 2015-12-15 WO PCT/US2015/065872 patent/WO2016100375A2/en not_active Ceased
- 2015-12-15 PT PT158708974T patent/PT3233192T/pt unknown
- 2015-12-15 EP EP15870897.4A patent/EP3233192B1/en active Active
- 2015-12-15 DK DK15870897.4T patent/DK3233192T3/da active
- 2015-12-15 US US15/536,580 patent/US10793613B2/en active Active
- 2015-12-15 ES ES15870897T patent/ES2881374T3/es active Active
-
2020
- 2020-08-18 US US16/996,265 patent/US11713342B2/en active Active
-
2023
- 2023-06-12 US US18/333,172 patent/US20240092854A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016100375A3 (en) | 2016-08-18 |
| US20240092854A1 (en) | 2024-03-21 |
| EP3233192A4 (en) | 2018-04-04 |
| DK3233192T3 (da) | 2021-07-19 |
| EP3875152B1 (en) | 2024-04-10 |
| EP3233192A2 (en) | 2017-10-25 |
| EP3233192B1 (en) | 2021-04-14 |
| US20190092831A1 (en) | 2019-03-28 |
| US20210032306A1 (en) | 2021-02-04 |
| EP4382535A3 (en) | 2024-08-21 |
| HRP20211113T1 (hr) | 2021-10-15 |
| HUE055460T2 (hu) | 2021-11-29 |
| EP3875152A1 (en) | 2021-09-08 |
| US10793613B2 (en) | 2020-10-06 |
| PT3233192T (pt) | 2021-07-19 |
| WO2016100375A2 (en) | 2016-06-23 |
| EP4382535A2 (en) | 2024-06-12 |
| ES2881374T3 (es) | 2021-11-29 |
| US11713342B2 (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE055460T2 (hu) | Készítmények és módszerek a célzott citokin bejuttatására | |
| IL258230A (en) | Oligonucleotide preparations and methods thereof | |
| IL256603A (en) | Preparations of oligonucleotides and methods | |
| GB2535253B (en) | Compositions and methods | |
| GB2546350B (en) | Compositions and methods | |
| IL249637B (en) | Methods and compositions for targeted genetic modifications and methods for use | |
| SG10202109655VA (en) | Compositions and methods for immunooncology | |
| ZA201702213B (en) | Interleukin-15 compositions and uses thereof | |
| EP3151846A4 (en) | Methods and compositions for nuclease design | |
| GB201718876D0 (en) | Antithrombin-heparin compositions and methods | |
| IL246879A0 (en) | Preparations of Epilimod and methods of using them | |
| GB201417828D0 (en) | New methods and compositions | |
| IL259894A (en) | Improved compositions and improved methods for viral delivery of neoepitopes and their use | |
| EP3116489A4 (en) | Methods and compositions for transdermal delivery | |
| GB201405651D0 (en) | Delivering an action | |
| SG11201701402QA (en) | Anti-tumor compositions and methods | |
| GB2537548B (en) | Set-delayed cement compositions comprising pumice and associated methods | |
| GB201512996D0 (en) | Compositions and methods | |
| PL3615005T3 (pl) | Kompozycje i sposoby dostarczania szczepionki | |
| IL248863A0 (en) | Preparations containing il-31 and their use | |
| GB201514413D0 (en) | Compositions and methods | |
| GB201402915D0 (en) | Compositions and methods | |
| IL256261B (en) | Hide1 compositions and methods | |
| HK1259505A1 (en) | Delivery methods and compositions | |
| GB201419559D0 (en) | Therapeutic compositions and methods |